GlassScriptPhysician profile
Leah C Wydro
NPI 1073996385
$2,364.58
in general payments reported to CMS, 2019-2025
26 companies · $171 in 2025
The $171 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $60.15 · 2021: $168 · 2022: $340 · 2023: $418 · 2024: $221 · 2025: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $810.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $359.54 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $250.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $247.04 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Genentech USA, INC. | $199.98 | 2019 | |
| Mallinckrodt Hospital Products INC. | $178.42 | 2021-2023 | Acthar |
| Boston Scientific Corporation | $121.70 | 2019 | |
| Abbott Laboratories | $117.83 | 2019 | |
| Insmed, INC. | $109.72 | 2019-2025 | Arikayce |
| Glaxosmithkline, LLC. | $100.49 | 2021-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Genzyme Corporation | $86.91 | 2021-2023 | |
| Axsome Therapeutics, INC. | $81.23 | 2023-2025 | Sunosi |
| Edwards Lifesciences Corporation | $76.33 | 2023 | Hemosphere |
| Regeneron Healthcare Solutions, INC. | $72.80 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.30 | 2022-2024 | Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $42.73 | 2022-2024 | Glassia |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $40.24 | 2021-2022 | |
| Harmony Biosciences LLC | $32.60 | 2023 | Wakix |
| Gilead Sciences, INC. | $29.15 | 2021-2022 | |
| Mylan Specialty L.P. | $27.41 | 2024 | Yupelri |
| United Therapeutics Corporation | $26.76 | 2021-2023 | Tyvaso |
| Ani Pharmaceuticals, INC. | $25.94 | 2023 | Purified Cortrophin Gel |
| Baxter Healthcare | $22.22 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $21.03 | 2022 | |
| Zoll Respicardia, INC. | $17.88 | 2024 | Remede System |
| Paratek Pharmaceuticals, INC. | $13.97 | 2025 | Nuzyra |
| La Jolla Pharmaceutical Company | $12.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leah Wydro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.